Study Designed to Evaluate Atossa's Combination Therapy AT-H201 to Reduce Patient Time on a Ventilator
SEATTLE — The fatality rate for COVID-19 victims on ventilators has been 50% or higher. So, at Atossa Therapeutics in...
The COVID-19 HOPE trial is the first pharmaceutical study to address getting patients off mechanical ventilator and reducing the high...
U.S. Physician Scientist Dr. Steven Quay, MD, PhD offers his predictions based on Coronavirus case growth model
Virtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests
Listen to the show below.
Sign Up to Stay Informed